| Co-Investigator(Kenkyū-buntansha) |
TAHARA Hideaki 東京大学, 医科学研究所, 教授 (70322071)
MATSUSHITA Marimo (SATO Marimo) 東京大学, 医科学研究所, 助教 (50401253)
KANAMOTO Akira 東京大学, 医科学研究所, 助教 (平成22 年度から平成23 年度まで) (10386021)
NAKAMUTA Takahumi 鳥取大学, 医学部, 准教授 (70432911)
KATANO Harutaka 国立感染症研究所, 感染病理部, 室長 (平成23 年度からは連携研究者) (70321867)
|
|---|
| Budget Amount *help |
¥19,500,000 (Direct Cost: ¥15,000,000、Indirect Cost: ¥4,500,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2011: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2010: ¥11,700,000 (Direct Cost: ¥9,000,000、Indirect Cost: ¥2,700,000)
|
|---|
| Research Abstract |
Autologous cell therapy serves as hindrance to implement a smooth clinical test, if that the quality of the cells as test medicine prepared from the patient itself differs for every case makes difficult the stable supply of the quality cell linking directly to a success of medical treatment. In this research, development of quality prediction / rationalization system in the private cell therapy which can conquer individual specificity by using more appropriated patient origin cell was considered by minimizing a risk of affecting the safety of trial drugs, such as revitalization of the incubation virus resulting from a patient individual's virus disease history, and an after-medication dynamic state.
|
